LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia

Exclusion Criteria

• •Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer
• •Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first LBH589 treatment
• •Peripheral neuropathy CTCAE grade 2 or higher
• •Impaired cardiac function or clinically significant cardiac diseases
• •Impairment of GI function or GI disease that may significantly alter the absorption of LBH589
• •Diarrhea \> CTCAE grade 1
• •Other concurrent severe and/or uncontrolled medical conditions including abnormal laboratory values, that could cause unacceptable safety risks or compromise compliance with the protocol
• •Patients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drug
• •Patients who have received targeted agents within 2 weeks or within 5 half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapies
• •Patients who have received chemotherapy or rituximab within 3 weeks or less; or radiation therapy to \> 30% of marrow-bearing bone within 2 weeks or less prior to starting study treatment; or who have not yet recovered from side effects of such therapies
• •Patients who have received corticosteroids 2 weeks or less prior to registration. Patients may be receiving chronic corticosteroids if they are being given for disorders other than than Waldenstrom's Macroglobulinemia
• •Patients with active bleeding tendency or receiving any treatment with therapeutic doses of sodium warfarin or coumadin derivatives. Low doses of Coumadin to maintain line patency is allowed
• •Patients who have undergone major surgery 4 weeks or less prior to starting study drug or who have not recovered from side effects of such therapy
• •Women who are pregnant or breast feeding or women of childbearing potential not using an effective method of birth control
• •Male patients whose sexual partners are women of childbearing potential not using effective methods of birth control
• •Patients with prior malignancy within the last 5 years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix)
• •Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
• •Patients with a significant history of non-compliance to medical regimens or unwilling or unable to comply with the instructions given to him/her by the study staff